echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Huadong Medicine Class 1 biopharmaceutical IMGN853 was approved for clinical use

    Huadong Medicine Class 1 biopharmaceutical IMGN853 was approved for clinical use

    • Last Update: 2021-04-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 30, the Sino-US East China Class 1 biopharmaceutical IMGN853 (Mirvetuximab Soravtansine), a subsidiary of East China Medicine, was approved for clinical use.


    IMGN853 is an antibody-drug conjugate (ADC) targeting FRα developed by ImmunoGen of the United States.


    IMGN853 is an antibody-conjugated drug containing FRα (folate receptor) binding antibody, cleavable linker and maytansinoid DM4, which is a powerful tubulin targeting agent.


    This product is the world's first ADC drug under development for FRα-positive ovarian cancer.


    Both Phase I (IMGN853-0401) and Phase III (IMGN853-0403) studies in the United States have consistently concluded that FRα high-expressing ovarian cancer can benefit from MIRV treatment.


    At present, only two imported foreign drugs, Kadcyla and Adcetris, were approved by the NMPA for marketing in January and May 2020 in China.


    The IMGN853 clinical approval in China is another progress in the research and development of this new drug.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.